We aim to list an easily understandable description of any MDS clinical trials currently opened to recruitment in the UK.
Patients will be able to read up on the details of these trials and use this information to discuss with their consultants or nurses. If you'd like more information about what a clinical trial is and how it is conducted, please go to this section.
Not all patients can be enrolled in drug trials - as not every patient will fit the necessary inclusion criteria, which need to be followed very strictly.
However, if a particular clinical trial drug is considered an option by the haematologist, it is sometimes possible to obtain the drug outside the trial, on the basis of compassionate use.
All the trials listed in this page have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - and to the UK MDS Forum for their continuous work in updating this listing.
Learn more about the latest MDS research
MDS Clinical Trials
Name of trial drug: Luspatercept, a protein found to promote red blood cell formation by regulating the growth of red blood cells during the late-stage of their development. It works differently to erythropoietin. For what level of MDS severity risk: Low or Intermediate What subtype of MDS: IPSS-R of very low, low or intermediate and ring sideroblasts […]Read full story
Name of trial drug: Lenalidomide For what level of MDS severity risk: Low or Intermediate What subtype of MDS: Del 5q Low or Intermediate-1 Risk Aims and benefits: This trial will investigate how lenalidomide, Revlimid®, affects the disease progression of patients with transfusion dependent MDS. This is a registry, non-interventional study. Read MoreRead full story
Name of trial drug: Oral Azacitidine For what level of MDS severity risk: Low What subtype of MDS: Those who need red blood cell transfusions Aims and benefits: To investigate the efficacy and safety of Oral Azacitidine + Best Supportive Care VERSUS Placebo + Best Supportive Care Read MoreRead full story
Name of trial drug: Rigosertib For what level of MDS severity risk: All What subtype of MDS: All Aims and benefits: This trial will investigate the survival of MDS patients receiving intravenous Rigosertib after failure of treatment with a Hypomethylating agent (HMA), Azacitidine (aza) or Decitabine (DEC) Read MoreRead full story
Name of trial drug: Eltrombopag, Promacta™/Revolade™ For what level of MDS severity risk: intermediate 1 & 2 or high risk What subtype of MDS: All who are platelet transfusion dependent Aims and benefits: Study will assess the proportion of patients who are platelet transfusion free during the first four cycles of treatment Read MoreRead full story